XMLUI conversion

7.4 The transition to electric mobility must be accompanied by a transition to car sharing.

2 Transfer to Insuman Rapid

11 Transfer to Insuman Rapid

20 Transfer to Insuman Rapid

Transfer to Insuman Rapid

Transfer to Insuman Basal

Elderly patients There is no evidence currently available to indicate that dosing should be adjusted in elderly patients.

Switching to other treatments

18 Switching to other treatments

32 Switching to other treatments

Transfer to Insuman Comb 15

Transfer to Insuman Comb 25

Transfer to Insuman Comb 50

290 Transfer to Insuman Infusat

299 Transfer to Insuman Infusat

Computerised customs checks

When converting from Prograf capsules to Advagraf tacrolimus trough levels should be measured prior to conversion and within two weeks after conversion.

2 Transfer to Insulin Human Winthrop Rapid

11 Transfer to Insulin Human Winthrop Rapid

20 Transfer to Insulin Human Winthrop Rapid

Transfer to Insulin Human Winthrop Rapid

Transfer to Insulin Human Winthrop Basal

Transition from other insulins to Lantus

Transition from other insulins to Optisulin

3.1 Moving towards evidence based sport policies

Transfer to Insulin Human Winthrop Comb 15

Transfer to Insulin Human Winthrop Comb 25

Transfer to Insulin Human Winthrop Comb 50

292 Transfer to Insulin Human Winthrop Infusat

301 Transfer to Insulin Human Winthrop Infusat

Overall assessment of their changeover to the euro

their overall assessment of their changeover to the euro.

Subject Migration to an open API

In the near future transition into emulsions is expected.

Switching to other antipsychotic medicinal products There are no systematically collected data to specifically address switching patients from ZYPADHERA to other antipsychotic medicinal products.

20 Care should be taken when converting patients from ciclosporin based to Invented name based therapy (see sections 4.4 and 4.5). Invented name therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient.

Conversion from ciclosporin Care should be taken when converting patients from ciclosporin based to Invented name based therapy (see sections 4.4 and 4.5). Invented name therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient.

Switching to other antipsychotic medicinal products There are no systematically collected data to specifically address switching patients from INVEGA to other antipsychotic medicinal products.

the possible effects of changing to different time zones,

timing of meals and insulin administration while travelling,

what you should do in emergency situations when you feel unwell or become ill.

Switching from Pradaxa treatment to parenteral anticoagulant

Switching from Pradaxa treatment to parenteral anticoagulant

Also the switch to renewable energy sources has been slow.